Literature DB >> 2703384

Characteristics of fluorinated nitroazoles as hypoxic cell radiosensitizers.

Y Shibamoto1, S Nishimoto, K Shimokawa, Y Hisanaga, L Zhou, J Wang, K Sasai, M Takahashi, M Abe, T Kagiya.   

Abstract

Types of 2-nitroimidazoles and 3-nitro-1,2,4-triazoles bearing one or two fluorine atoms on their side chains were synthesized to evaluate their physicochemical properties, radiosensitizing effects, and toxicity. The reduction potential of the compounds containing one fluorine was similar to that of misonidazole (MISO), whereas that of the difluorinated compounds was slightly higher. Both mono- and difluorinated compounds had an in vitro sensitizing activity comparable to or slightly higher than that of MISO. The fluorinated 3-nitrotriazoles were almost as efficient as the 2-nitroimidazoles with the same substituent. In vivo, some of the compounds were up to twice more efficient than MISO, whereas others were as efficient as MISO. Toxicity in terms of LD50/7 in mice was quite variable depending on the side-chain structure; the amide derivatives were less toxic than MISO, whereas the alcohol and ether derivatives were more toxic. In view of the radiosensitizing effect and toxicity in vivo, at least one compound, KU-2285 (a 2-nitroimidazole with an N1-substituent of: CH2CF2CONHCH2CH2OH) has been found to be as useful a hypoxic cell sensitizer as SR-2508.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2703384     DOI: 10.1016/0360-3016(89)90912-7

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  6 in total

1.  Tirapazamine: hypoxic cytotoxicity and interaction with radiation as assessed by the micronucleus assay.

Authors:  T Shibata; Y Shibamoto; K Sasai; N Oya; R Murata; T Takagi; M Hiraoka; M Takahashi; M Abe
Journal:  Br J Cancer Suppl       Date:  1996-07

2.  KIH-802, an acetohydroxamic acid derivative of 2-nitroimidazole, as a new potent hypoxic cell radiosensitizer: radiosensitizing activity, acute toxicity, and pharmacokinetics.

Authors:  K Sasai; Y Shibamoto; M Takahashi; L Zhou; H Hori; H Nagasawa; T Shibata; S Inayama; M Abe
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  A phase I/II study of a hypoxic cell radiosensitizer KU-2285 in combination with intraoperative radiotherapy.

Authors:  Y Shibamoto; G Ohshio; R Hosotani; Y Nishimura; T Manabe; M Imamura; M Abe
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

4.  A new, potent 2-nitroimidazole nucleoside hypoxic cell radiosensitizer, RP170.

Authors:  K Sasai; Y Shibamoto; M Takahashi; M Abe; J Wang; L Zhou; S Nishimoto; T Kagiya
Journal:  Jpn J Cancer Res       Date:  1989-11

5.  A novel class of antitumor prodrug, 1-(2'-oxopropyl)-5-fluorouracil (OFU001), that releases 5-fluorouracil upon hypoxic irradiation.

Authors:  Y Shibamoto; L Zhou; H Hatta; M Mori; S Nishimoto
Journal:  Jpn J Cancer Res       Date:  2000-04

6.  Comparison of in vivo efficacy of hypoxic cytotoxin tirapazamine and hypoxic cell radiosensitizer KU-2285 in combination with single and fractionated irradiation.

Authors:  T Shibata; Y Shibamoto; K Sasai; N Oya; R Murata; T Takagi; M Hiraoka; M Abe
Journal:  Jpn J Cancer Res       Date:  1996-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.